Your browser doesn't support javascript.
loading
Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
Zhang, Yuchen; Liu, Panpan; Cai, Jun; Jing, Hongmei; Zou, Liqun; Huang, Huiqiang; Wu, Yuanbin; Li, Wenyu; Zhong, Liye; Jin, Xueli; Ye, Xu; Feng, Ru; Zhang, Huilai; Zhang, Liling; Lin, Lie; Sun, Xiuhua; Tian, Yuyang; Xia, Zhongjun; Li, Zhiming; Huang, He; Xia, Yi; Cai, Qingqing.
Affiliation
  • Zhang Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Liu P; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Cai J; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Jing H; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Zou L; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Huang H; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Wu Y; Department of Hematology, Peking University Third Hospital, Beijing, P.R. China.
  • Li W; Department of Oncology, West China Hospital, Sichuan University, Chengdu, P.R. China.
  • Zhong L; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Jin X; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Ye X; Department of Hematology, Guangdong Province Traditional Chinese Medical Hospital, Guangzhou, P.R. China.
  • Feng R; Division of Lymphoma, Department of Clinical Oncology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Zhang H; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, P.R. China.
  • Zhang L; Department of Hematology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P.R. China.
  • Lin L; Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R. China.
  • Sun X; Department of Hematology, Nanfang Hospital of Nanfang Medical University, Guangzhou, P.R. China.
  • Tian Y; Department of Lymphoma, Tianjin Medical University Cancer Hospital and Institute, Tianjin, P.R. China.
  • Xia Z; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China.
  • Li Z; Department of Hematology, Hainan General Hospital, Haikou, P.R. China.
  • Huang H; Myeloma and Lymphoma Research Center, Second Affiliated Hospital of Dalian Medical University, Dalian, P.R. China.
  • Xia Y; Department of Hematology, Hainan Cancer Hospital, Haikou, P.R. China.
  • Cai Q; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
Cancer Med ; 11(22): 4134-4145, 2022 11.
Article in En | MEDLINE | ID: mdl-35438258
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Mantle-Cell Type of study: Observational_studies Limits: Adult / Humans / Male Language: En Journal: Cancer Med Year: 2022 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Mantle-Cell Type of study: Observational_studies Limits: Adult / Humans / Male Language: En Journal: Cancer Med Year: 2022 Document type: Article Country of publication: United States